Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK completes Sirtris acquisition

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline acquires Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer and merger of $22.50 per share, the firms state June 6. The buy significantly enhances GSK's "metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process," according to the London-based firm. Sirtris' lead compound is resveratrol based (1"The Tan Sheet" April 28, 2008, In Brief)....

You may also be interested in...



GSK buys Sirtris

GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer of $22.50 per share, which is an 84 percent premium on Sirtris' closing price April 22 - the day the deal was announced. GSK says the acquisition will "significantly enhance its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins," a seven-member family of proteins long thought to play a role in the aging process, with "potentially transformative" benefits addressing diseases such as diabetes, muscle wasting and neuron-degeneration. Sirtris' lead compound, the resveratrol formulation SRT501, "significantly" lowered glucose in an oral glucose tolerance test conducted as part of a 28-day Phase 1b clinical study in type 2 diabetes patients, the firm said in January (1"The Tan Sheet" Jan. 14. 2008, In Brief). Sirtris will become part of GSK's Drug Discovery division while operating in Cambridge, Mass., as an autonomous unit. The deal is subject to closing conditions, but the firms expect the tender offer to commence in May and close in the second quarter of 2008...

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel